韩
韩永贵 Chief Technology Officer
Other
FR FR · AMF
Browse the full record of transactions filed by 韩永贵, Chief Technology Officer. Insider active across 1 companies, notably 惠泰医疗. Cumulatively, 44 disclosures have been recorded. Regulator: AMF. The full history is free.
Declarations 44 total
Executives ● Purchase惠 惠泰医疗 7 SSE 10,000 shares
SSE:273000000615639230 · 14 May 2026
Ideal exit: 8 Feb 2027 (T+270) Executives ● Purchase一 一心堂 7 SZSE 1,359,000 shares
SZSE:273000000606293660 · 12 May 2026
Ideal exit: 6 Feb 2027 (T+270) Executives ● Purchase广 广钢气体 12 SSE 4,596 shares
SSE:273000000183673820 · 10 Feb 2026
Ideal exit: 7 Nov 2026 (T+270) Executives ● Purchase一 一心堂 7 SZSE 1,550,700 shares
SZSE:273000000037371620 · 17 Dec 2025
Ideal exit: 13 Sept 2026 (T+270) 1,761,400 shares
SZSE:273000000037884160 · 17 Dec 2025
Executives ● Sale英 英诺激光 22 SZSE 2,800 shares
SZSE:173000009573067170 · 22 Sept 2025
2,164,739 shares
SSE:173000009518584320 · 11 Sept 2025
Executives ● Sale惠 惠泰医疗 11 SSE 29,943 shares
SSE:173000008879613900 · 29 Apr 2025
Executives ● Purchase广 广钢气体 8 SSE 10,100 shares
SSE:173000008783476450 · 10 Apr 2025
Ideal exit: 5 Jan 2026 (T+270) Executives ● Purchase全 全筑股份 7 SSE 81,800 shares
SSE:173000008362519230 · 19 Dec 2024
Ideal exit: 15 Sept 2025 (T+270) Executives ● Purchase广 广钢气体 8 SSE 84,440 shares
SSE:173000008117076500 · 24 Sept 2024
Ideal exit: 21 Jun 2025 (T+270) Executives ● Purchase全 全筑股份 7 SSE 89,900 shares
SSE:173000008109353950 · 20 Sept 2024
Ideal exit: 17 Jun 2025 (T+270) Executives ● Purchase全 全筑股份 7 SSE 88,500 shares
SSE:173000008109354000 · 20 Sept 2024
Ideal exit: 17 Jun 2025 (T+270) Executives ● Purchase全 全筑股份 7 SSE 40,000 shares
SSE:173000008106818050 · 19 Sept 2024
Ideal exit: 16 Jun 2025 (T+270) Executives ● Purchase全 全筑股份 7 SSE 203,300 shares
SSE:173000008103651200 · 18 Sept 2024
Ideal exit: 15 Jun 2025 (T+270) Executives ● Purchase英 英诺激光 23 SZSE 3,000 shares
SZSE:173000007946740350 · 12 Aug 2024
Ideal exit: 9 May 2025 (T+270) Executives ● Purchase英 英诺激光 15 SZSE 200 shares
SZSE:173000007942541000 · 9 Aug 2024
Ideal exit: 6 May 2025 (T+270) Executives ● Purchase全 全筑股份 11 SSE 100,000 shares
SSE:173000007850657120 · 17 Jul 2024
Ideal exit: 13 Apr 2025 (T+270) Executives ● Purchase华 华英农业 14 SZSE 174,300 shares
SZSE:173000007639761180 · 13 May 2024
Ideal exit: 7 Feb 2025 (T+270) Executives ● Purchase英 英诺激光 19 SZSE 6,300 shares
SZSE:173000007502898900 · 16 Apr 2024
Ideal exit: 11 Jan 2025 (T+270) Executives ● Purchase英 英诺激光 19 SZSE 5,900 shares
SZSE:173000007498554430 · 15 Apr 2024
Ideal exit: 10 Jan 2025 (T+270) Executives ● Purchase华 华英农业 7 SZSE 2,437,400 shares
SZSE:173000007381152740 · 8 Mar 2024
Ideal exit: 3 Dec 2024 (T+270) 2,374 shares
SSE:173000007307411260 · 5 Feb 2024
Executives ● Purchase一 一心堂 7 SZSE 23,800 shares
SZSE:173000007180783360 · 21 Dec 2023
Ideal exit: 16 Sept 2024 (T+270) Executives ● Purchase广 广钢气体 12 SSE 20,000 shares
SSE:173000006825130300 · 21 Aug 2023
Ideal exit: 17 May 2024 (T+270) 25 of 44 declarations
Load more (19 remaining) About 韩永贵 Han Yonggui is a Chief Technology Officer at Huatai Medical. He plays a key role in developing innovative medical solutions, focusing on improving health technologies. With his technical expertise and strategic vision, he contributes to advancing the company's projects.